UNSPSC 51281811: Detorubicin

This classification denotes an anthracycline antibiotic with the molecular formula C33H39NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 822EC3XEJZ, chemically known as glyoxylic acid 3(sup 2)-ester with doxorubicin, 2-(diethyl acetal) but generally known as detorubicin, which bears US NIH Compound Identifier 114806. European Medicines Agency schedules Detorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07013MIG.

UNSPSC 51281811 Detorubicin, a Commodity code, shows minimal recent state and local procurement activity directly aligned with the code's pharmaceutical scope. The most recent opportunities tagged under this code involve naloxone procurement, medical and first aid supplies for emergency responders, generic pharmaceuticals through cooperative purchasing, and a preliminary market-intelligence RFI on direct-to-manufacturer pharmacy programs—a range suggesting either misclassification or a code used as a catch-all for diverse pharmaceutical and medical-supply categories rather than doxorubicin-class chemotherapy agents specifically. State and local buyers soliciting under this code include county health departments, municipal fire and emergency services, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida and the City of Tampa have posted recent opportunities; Texas HHS and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent state-level and regional cooperative buyers.

Activity is concentrated in Florida and the upper Midwest (Minnesota, with Oregon participation through MMCAP), with Texas HHS conducting preliminary market research. The Seminole County IFB (IFB60459723LAS) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The City of Tampa issued an IFB (26P00145) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, with an estimated contract value of $700,000 and response due March 13, 2026, designated exclusively for certified Small Local Business Enterprises at a 5 percent bid discount not to exceed $10,000. MMCAP released an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, proposals due March 26, 2026, with awards effective July 1, 2026. Texas HHS posted an RFI (HHS0017013) exploring vendor capability for direct-to-manufacturer prescription programs, response due April 3, 2026. The code's activity does not consistently reflect detorubicin procurement; business development should verify code alignment with actual oncology pharmaceutical sourcing before committing resources.